LoginSignup
Novo Nordisk A/S Class B logo

Novo Nordisk A/S Class B

Stock
Stock
ISIN: DK0062498333
Ticker: NOVO B
DK0062498333
NOVO B

Price

Price

CHART BY

Historical dividends and forecast

All dividend data

Novo Nordisk A/S Class B has so far distributed $1.811 in 2026. The next dividend will be paid on 31.03.2027

$0.355

CHART BY

Frequently asked questions

The market capitalization of Novo Nordisk A/S Class B is $188.72B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
The Price-to-Earnings (P/E) ratio (TTM) for Novo Nordisk A/S Class B is 10.54. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
Novo Nordisk A/S Class B's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $4.049. EPS indicates the company's profitability on a per-share basis.
Currently, 33 analysts cover Novo Nordisk A/S Class B's stock, with a consensus target price of $48.92. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Novo Nordisk A/S Class B reported a revenue of $50.87B.
Novo Nordisk A/S Class B's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $26.23B. EBITDA measures the company's overall financial performance.
Novo Nordisk A/S Class B has a free cash flow of $11.51B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Novo Nordisk A/S Class B employs approximately 68,794 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
The free float of Novo Nordisk A/S Class B is 3.15B. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$188.72B
EPS (TTM) 
$4.049
Free Float 
3.15B
P/E ratio (TTM) 
10.54
Revenue (TTM) 
$50.87B
EBITDA (TTM) 
$26.23B
Free Cashflow (TTM) 
$11.51B

Pricing

1D span
$42.48$43.58
52W span
$34.81$65.10

Analyst Ratings

The price target is $48.92 and the stock is covered by 33 analysts.

Buy

9

Hold

19

Sell

5

Information

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Employees
68,794
Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

ISIN
DK0062498333
Primary Ticker
NOVO B

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin